Inhibitors of the interaction between P53 and MDM2

US7083983B2 · kind B2 · utility

Assignee

• Cancer Research Campaign Technology Limited · GB

Inventors

• David Philip Lane · Dundee, GB
• Volker Böttger · Germering, DE
• Angelika Bottger · Germering, DE
• Steven Michael Picksley · Bradford, GB
• Heinz-Kurt Hochkeppel · Aesch, CH
• Carlos Garcia-Echeverria · Basel, CH
• Patrick Chene · Mulhouse, FR
• Pascal Furet · Basel, CH

Key dates

• Filing date: Jul 4, 1997
• Grant date: Aug 1, 2006
• Expiry date: Jul 4, 2017

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to compounds capable of binding to the oncogene protein MDM2, processes for the preparation of such compounds, pharmaceutical preparations comprising such compounds, and uses of said compounds, e.g. in the therapeutic (including prophylactic) treatment of an animal or especially of the human body. The present further relates to methods of and compounds for inhibiting the growth of tumor cells which comprise the wild type p53 suppressor by interfering with the interaction between human p53 and human MDM2.